Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 08, 2026 05:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments extra bolagsstämma 2026

STOCKHOLM, SVERIGE – 8 januari 2026. Karolinska Development AB (publ) (”Karolinska Development” eller ”Bolaget”) har den 8 januari 2026 hållit extra bolagsstämma, varvid aktieägarna beslutade...
January 08, 2026 05:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s Extraordinary General Meeting 2026

STOCKHOLM, SWEDEN – January 8, 2026. Karolinska Development AB (publ) (“Karolinska Development” or the “Company”) held an Extraordinary General Meeting on January 8, 2026, at which the shareholders...
December 22, 2025 02:17 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines planerar notering på Nasdaq First North Premier genom ett omvänt förvärv inför accelererad vaccinutveckling

STOCKHOLM, 22 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines AB har ingått en icke-bindande avsiktsförklaring med Novakand Pharma AB...
December 22, 2025 02:17 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines plans for listing on Nasdaq First North Premier through reverse takeover ahead of accelerated vaccine development

STOCKHOLM, Sweden, December 22, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has signed a non-binding letter of intent (LOI) with Novakand...
December 11, 2025 02:28 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag SVF Vaccines presenterar nya prekliniska data som visar långtidseffekt av SVF-001 mot kronisk hepatit B och D

STOCKHOLM, 11 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget SVF Vaccines har presenterat nya prekliniska resultat för bolagets immunterapi SVF-001...
December 11, 2025 02:28 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company SVF Vaccines presents new preclinical data demonstrating extended effect of SVF-001 in chronic hepatitis B and D

STOCKHOLM, Sweden, December 11, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has presented new preclinical data on its immunotherapy...
December 10, 2025 07:05 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag Modus Therapeutics inleder doseringen i en klinisk fas 2a-studie i patienter med kronisk njursjukdom med anemi

STOCKHOLM, 10 december, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Modus Therapeutics har doserat den första patienten i den kliniska fas 2a-studien som...
December 10, 2025 07:05 ET | Source: Karolinska Development AB (publ)

Karolinska Development's portfolio company Modus Therapeutics initiates dosing in phase 2a study in patients with chronic kidney disease with anemia

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company, Modus Therapeutics, has dosed the first patient in the phase 2a...
December 10, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Developments portföljbolag AnaCardio presenterar positiva top line-resultat från fas 2a-studien med läkemedelskandidaten AC01

STOCKHOLM, 10 december 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio presenterat starka och positiva top line-resultat från den kliniska fas...
December 10, 2025 02:00 ET | Source: Karolinska Development AB (publ)

Karolinska Development’s portfolio company AnaCardio presents positive top-line data from the phase 2a study of its drug candidate AC01

STOCKHOLM, SWEDEN December 10, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has reported strong, positive results from the phase 2a...